|
|
News Breaks
|
November 9, 2009
|
| 09:02 EDT |  | SHPGY |
| theflyonthewall.com: | Shire announces availability of Intuniv ER tablets | | Shire announced the availability of INTUNIV(TM) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. In clinical trials, INTUNIV provided significant efficacy across the spectrum of ADHD symptoms that can be disruptive, such as being easily distracted, interrupting others, running around excessively, arguing with adults, and losing temper. :theflyonthewall.com |
|
|
News For SHPGY From The Last 14 Days Check below for free stories on SHPGY the last two weeks.
There are 10 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 08:00 EDT |  | SHPGY |
|
|
February 9, 2012
|
| 10:01 EDT | | SHPGY |
| | 09:57 EDT | | SHPGY |
| | 09:57 EDT | | SHPGY |
| theflyonthewall.com: | Shire says sees 2012 gross margins "marginally lower" | | Says will reflect the FY impact of ABH acquisition. :theflyonthewall.com |
| | 09:56 EDT | | SHPGY |
| | 07:20 EDT |  | SHPGY |
| | 07:17 EDT | | SHPGY |
| theflyonthewall.com: | Shire reports Q4 adjusted EPS $1.51 vs. consensus $1.37 | | Reports Q4 revenue $1.14B vs. consensus $1.13B. :theflyonthewall.com |
|
|
February 7, 2012
|
| 12:20 EDT | | SHPGY |
| theflyonthewall.com: | Shire's Vyvanse gets FDA approval as maintenence treatment in adults with ADHD | | Shire announced that the FDA approved the prescription medication Vyvanse Capsules as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse in adults who were receiving treatment with Vyvanse for a minimum of 6 months prior to enrolling in the study. Significantly more patients treated with Vyvanse maintained ADHD symptom control compared with placebo as determined by the proportion of patients who met criteria for relapse of symptoms at end point during the six-week randomized double-blind withdrawal phase of the study. This new approval adds to the indication for Vyvanse as a treatment for ADHD in patients ages 6 and above. :theflyonthewall.com |
|
|
February 1, 2012
|
| 07:24 EDT | | SHPGY |
|
|
January 30, 2012
|
| 07:29 EDT |  | SHPGY |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information